Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Therapeutic Modalities | Industry Spotlights & Insight Articles

Immunostimulatory Oncolytic Viruses: Interview with Angelica Loskog, CEO, Lokon Pharma

Edited by Tom Cohen | 14 November 2023
Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.
https://www.youtube.com/watch?v=Uo1WsUGIEq0&ab_channel=OxfordGlobal

We had the privilege of sitting down with Angelica Loskog, Professor of Immunotherapy at Uppsala University in Sweden and the CEO of Lokon Pharma, a cutting-edge immunotherapy company making strides in the field. As a leader in the realm of oncolytic viruses and immunostimulatory gene therapy, Professor Loskog shared valuable insights into Lokon Pharma's groundbreaking work.

RELATED:

Speaker Biographies

Angelica has over 20 years immune oncology experience (Uppsala University and Baylor College of Medicine). She has a PhD in Medical Sciences from Uppsala University and is currently adjunct as a Professor of immunotherapy. She is an advisor to NEXTTOBE and is a board member of several of their portfolio companies.

Related Resources

Positive Results from iNKT Cell Therapy Clinical Trial for COVID-19 ARDS

The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19.
Read More

How to Improve Therapeutic Efficacy: Safety Considerations in Oncolytic Virotherapy

Oncolytic virotherapy targets cancer cells with viruses, promising personalized treatment with minimal side effects. Safety measures include minimizing off-target effects and systemic spread. Combining with immunotherapy enhances efficacy, revolutionizing cancer treatment.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
08/04/24
Harnessing The Immune System With NK Cell Engagers
01/11/24
Immunotherapies For Solid Tumour Targeting